LXRP News and Press, Lexaria Bioscience Corp. From 09/22/20

Lexaria Bioscience (LXRP) has been granted U.S. Patent No. 10,756,180, entitled "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof".This new patent provides patent claims that protect the use of Lexaria's DehydraTECH technology together with ...

(TheNewswire) Kelowna, British Columbia - TheNewswire - September 22, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announces ...

(via TheNewswire) Kelowna, British Columbia - TheNewswire - September 16, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, proudly supports the corporate growth initiati...

KELOWNA, BC / ACCESSWIRE / August 31, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a research and development ("R&D") framework agreement with British American Tobacco (Inv...

(via TheNewswire) Kelowna, British Columbia - TheNewswire - August 31, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a research and deve...

Company to discuss its Phase I R&D program with Altria Ventures Inc., for oral forms of nicotine delivery utilizing its patented DehydraTECH™ technology LOS ANGELES, CA / ACCESSWIRE / August 20, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexa...

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...

Lexaria Bioscience ( OTCQX:LXRP +8.4% ) has received ethics board approval by a European university research hospital to conduct an exploratory study using cannabidiol (CBD) along with its DehydraTECH technology, to assess blood pressure reduction potential in patients with pre- or mild ...

Complements previously published data that cites Lexaria's TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure KELOWNA, BC / ACCESSWIRE / July 28, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in...

(via TheNewswire) Kelowna, British Columbia - TheNewswire - July 21, 2020 - Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has filed an application with a s...